Lineage Cell Therapeutics Files 8-K

TL;DR

Lineage Cell Therapeutics filed an 8-K on Aug 26, 2025, covering financial statements and other events.

AI Summary

Lineage Cell Therapeutics, Inc. filed an 8-K on August 26, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as BIOTIME INC, is incorporated in California and headquartered in Carlsbad.

Why It Matters

This 8-K filing provides an update on corporate events and financial information for Lineage Cell Therapeutics, Inc., which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting standard corporate events and financial information, not indicating any immediate significant risks.

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — Registrant
• BIOTIME INC (company) — Former company name
• August 26, 2025 (date) — Date of report
• Carlsbad, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $12 million — ss (the "Project"). WDI will fund up to $12 million in research collaboration costs over th

Filing Documents

• lctx-20250826.htm (8-K) — 47KB
• lctx-ex9_1.htm (EX-9.1) — 31KB
• img193828089_0.jpg (GRAPHIC) — 40KB
• 0000950170-25-111319.txt ( ) — 242KB
• lctx-20250826.xsd (EX-101.SCH) — 23KB
• lctx-20250826_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 26, 2025, Lineage Cell Therapeutics, Inc. ("we," "us," "our," the "Company," or "Lineage") issued a press release announcing that it entered into a multi-year research collaboration agreement with William Demant Invest 2 Aps ("WDI") to advance the preclinical development of Lineage's auditory neuronal cell transplant program, ReSonance TM (ANPI), for the treatment of hearing loss. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Item 7.01 and in Exhibit 99.1 to this report is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On August 22, 2025, Lineage and WDI entered into a research collaboration agreement (the "RCA") to advance the preclinical development of Lineage's auditory neuronal cell transplant program, ReSonance (ANPI), for the treatment of hearing loss (the "Project"). WDI will fund up to $12 million in research collaboration costs over the approximate three-year term of the RCA. The main objective of the RCA is for the parties to complete a preclinical phase achieving readiness to potentially progress to human clinical trials under one or more separate clinical agreements, the terms of which would be negotiated in good faith before the expiration of the RCA. All intellectual property owned by a party prior to the date of the RCA will remain their sole and exclusive property. The parties will jointly own all results, data, reports, know-how and patent(s) conceived or otherwise generated in the course of and resulting from the Project (the "Project Results"), other than discoveries or developments relating to Lineage's prioprietary platform technology. If a party (the "abandoning party") informs the other party (the "continuing party") that it will not continue the research with the other party under a clinical agreement, the continuing party may purchase the abandoning party's ownership interest in the intellectual property resulting from the Project for exploitation for the treatment of hearing loss and a license to the abandoning party's background intellectual property to the extent necessary for such exploitation for an amount and on terms to be determined by the mutual agreement of the parties, and if such mutual agreement is not reached, by an independent third-party.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued on August 26, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lineage Cell Therapeutics, Inc. Date: August 26, 2025 By: /s/ George A. Samuel III Name: Title: George A. Samuel III General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR